Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.47 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16774954 | 0.88 | SMN1; SMN2 (0.48) | SMPD3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1611981 | 0.85 | NR1H2 (0.52) | GPR119SMPD3PDE4APDE4BPDE4C | |
| SCHEMBL6773498 | 0.84 | ESR2 (0.51) | GPR119SMPD3PDE4APDE4BPDE4C | |
| SCHEMBL6947145 | 0.82 | GPR119 (0.55) | GPR119PARP14LMNASMN1; SMN2MEN1 | |
| SCHEMBL12632946 | 0.82 | CYP2C9 (0.58) | SMPD3LMNASMN1; SMN2MEN1POLB | |
| SCHEMBL20339474 | 0.82 | GPR119 (0.55) | GPR119PARP14LMNASMN1; SMN2MEN1 | |
| SCHEMBL15658458 | 0.82 | SMPD3 (0.49) | GPR119SMPD3PDE4APDE4BPDE4C | |
| SCHEMBL6772730 | 0.82 | STS (0.48) | GPR119SMPD3PDE4APDE4BPDE4C | |
| SCHEMBL1397384 | 0.82 | KDM4E (0.63) | POLBSLC2A1SLC2A2SLC2A3HTR1D | |
| SCHEMBL24027979 | 0.81 | ABCB1 (0.52) | GPR119SMPD3LMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946539-B1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-13 | — | — | EP | disclosed |
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | disclosed |
| US-6423717-B1 | NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-23 | — | — | US | disclosed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | GPR119 3715/4885SMPD3 141/4885PARP14 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.